$Oxis Biotech Inc. Announces Corporate Update Conference Call for March 31

TAMPA, Fla., March 25, 2015 /PRNewswire/ — Oxis International, Inc. (OXIS) (OXI.PA) a biotechnology company focused on cannabinoid therapy development and commercialization, announced today Oxis CEO Tony Cataldo will hold a conference call on Tuesday March 31, 2015 at 4:15pm EST to update shareholders and other interested parties on corporate developments at Oxis Biotech, Inc.

Oxis Chairman and CEO Tony Cataldo stated, “The first quarter of 2015 has been very exciting for Oxis and our shareholders. There is a lot going on inside Oxis and sometimes it is better to speak with our shareholders and market participants so everyone can understand what all of the excitement is about.  I am using  the same approach that I used when, as founder, I created Lion Biotechnologies, Inc. (LBIO) which has enjoyed dramatic success. We have acquired intellectual property assets, brought world class scientists on board, completed financings, and partnered with some of the best medical research facilities in the world.  Oxis, has grown dramatically and achieved significant milestones recently. We get lots of questions about Lion, Oxis, the comparisons between the two companies and our plans for the future. Some things just can’t be explained as well through news releases as through conversation. So, I am looking forward to speaking with shareholders and taking questions on March 31.”

Shareholders and interested parties are invited to participate in the conference call. The call will start promptly at 4:15pm EST on Tuesday, March 31, 2015. The dial in number for the call is 712.775.7031. Meeting ID number is 576-591-822.

Contact

Jonathan Barkman
Riverview Capital Enterprises
1275 Glenlivet Dr Ste 100
Allentown, PA 18106
office  866-845-0105
fax     484-224-2999

ABOUT OXIS BIOTECH, INC. – OXIS is a biotech company that develops and commercializes innovative drugs of therapeutic molecules including cannabinoids, which are focused on several cancer indications. Oxis address the clinical shortcomings of existing commercial products in related fields. OXIS has formed relationships with some of the worlds leading cannabinoid researchers and institutions to advance it’s technologies.

Forward-Looking Statements Except for historical information contained herein, the statements in this release are forward-looking and made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are inherently unreliable and actual results may differ materially. Examples of forward-looking statements in this news release include statements regarding the payment of dividends, marketing and distribution plans, development activities and anticipated operating results. Factors which could cause actual results to differ materially from these forward-looking statements include such factors as the Company’s ability to accomplish its business initiatives, significant fluctuations in marketing expenses and ability to achieve and expand significant levels of revenues, or recognize net income, from the sale of its products and services, as well as the introduction of competing products, or management’s ability to attract and maintain qualified personnel necessary for the development and commercialization of its planned products, and other information that may be detailed from time to time in the Company’s filings with the United States Securities and Exchange Commission. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.